Search results
Results from the WOW.Com Content Network
Inspire Medical’s outlook for 2025 is based on plans to hire more staff, open new centers, increase direct-to-consumer advertising, expand treatment indications, and boost capacity.
The FDA has labeled a recall of Inspire Medical Systems, Inc.’s (NYSE:INSP) nerve-stimulating implant for obstructive sleep apnea as Class I, the most serious kind. Inspire initiated a recall of ...
For additional information about Inspire, please visit www.inspiresleep.com. Investor and Media Contact Ezgi Yagci Vice President, Investor Relations ezgiyagci@inspiresleep.com 617-549-2443 11/06/2024 08:00 -0500
For additional information about Inspire, please visit www.inspiresleep.com. Investor and Media Contact Ezgi Yagci Vice President, Investor Relations ezgiyagci@inspiresleep.com 617-549-2443 11/15/2024 08:00 -0500
Inspire (INSP) delivered earnings and revenue surprises of 7.69% and 9.18%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
The accuracy of medical journalism varies widely. Reviews of mass media publications have graded most stories unsatisfactory, although there were examples of excellence. [2] [3] Other reviews have found that most errors in mass media publications were the result of repeating errors in the original journal articles or their press releases. [4]
Serious side effects may include heart attacks, stroke, increased cancer growth, or pure red cell aplasia. [2] It is unclear if use is safe during pregnancy. [5] [6] They work similar to naturally occurring erythropoietin. [1] They were first approved for medical use in the United States in 1989. [5]
Carbamazepine is an approved treatment for bipolar disorder and epileptic seizures, but it has side effects useful in treating attention-deficit hyperactivity disorder (ADHD), schizophrenia, phantom limb syndrome, paroxysmal extreme pain disorder, neuromyotonia, and post-traumatic stress disorder.